Leukaemia Trial, Recruiting NCT07048535 Sponsor: St. Jude Children's Research Hospital Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT07048535
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who were 26 years old or younger at the time of their first CAR T-cell treatment
  • People who received a CAR T-cell treatment targeting a protein called CD19, used to treat a type of blood cancer called B-cell acute lymphoblastic leukaemia (B-ALL)
  • People who received only one type of CAR T-cell product (receiving the same product more than once is allowed)
  • People whose cancer went into remission after CAR T-cell treatment and who did not need further treatment afterwards (an exception is made for a stem cell transplant given after the CAR T-cell treatment)
  • People who have had no more than one stem cell transplant in total, whether that was before or after their CAR T-cell treatment
  • People who are at least 2 years past their last CAR T-cell infusion

Who may not be able to join:

  • People who are unable or unwilling to provide written consent, or whose legal guardian or representative is unable or unwilling to do so on their behalf

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Aimee Talleur, MD, St. Jude Children's Research Hospital

Phone: 888-226-4343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
St. Jude Children's Research Hospital
Registry
ClinicalTrials.gov
Start date
24 October 2025
Est. completion
1 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To evaluate the feasibility of conducting standardized clinical assessments of pediatric and AYA B-ALL survivors post CD19-CAR T-cell therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov